PPIDT00078
Drug Information
| Name | Efalizumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS |
| DrugBank_ID | DB00095 |
| Type | biotech |
| Indication | For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Subcutaneous |
100 mg/ml
|
| Powder, for solution | Subcutaneous |
150 mg / vial
|
| Solution | Subcutaneous |
125.00 mg
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
12500000 mg
|